Metabolism

Digbi Health AI Powered Digital Therapeutics Platform for Polychronic Illnesses Expands to Manage Mental Health

Tuesday, September 21, 2021 - 12:00pm

MOUNTAIN VIEW, Calif., Sept. 21, 2021 /PRNewswire/ -- Digbi Health , an AI-powered, precision digital therapeutics platform that uses gut microbiome and host genetic information, expands its digital health platform to manage several mental health and psychiatric disorders under the FDA's Enforcement Policy for Digital Health Devices For Treating Psychiatric Disorders during the Coronavirus Public Health Emergency.

Key Points: 
  • MOUNTAIN VIEW, Calif., Sept. 21, 2021 /PRNewswire/ -- Digbi Health , an AI-powered, precision digital therapeutics platform that uses gut microbiome and host genetic information, expands its digital health platform to manage several mental health and psychiatric disorders under the FDA's Enforcement Policy for Digital Health Devices For Treating Psychiatric Disorders during the Coronavirus Public Health Emergency.
  • Digbi Mental Health was created to improve the mental health and well-being of members during periods of shelter-in-place, isolation and quarantine and serves as an adjunct to clinician-supervised, outpatient treatment to its members.
  • A real world study of 275 Digbi Health members reveals clinically significant reductions in Anxiety, Insomnia & Depression symptoms linked to improved gut health.
  • Available on the Blue Shield of California Wellvolution platform, Digbi Cares is a next-generation, prescription-grade digital therapeutic platform, polychronic mental and physical illness.

ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021

Monday, September 20, 2021 - 9:05pm

The 0.6 million increase in financial result was mostly related to foreign currency gains on U.S. dollar.

Key Points: 
  • The 0.6 million increase in financial result was mostly related to foreign currency gains on U.S. dollar.
  • As of June 30, 2021, ERYTECH had cash and cash equivalents totaling 46.3 million (approximately $54.9 million), compared with 44.4 million on December 31, 2020 and 37.4 million on March 31, 2021.
  • The Company believes that its current cash position can fund its planned operating expenses and current programs into the second quarter of 2022.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

National Advertising Division Finds Claim that Almased Diet and Weight Loss Program is "So Safe that Even People with Diabetes Can Use It" Supported

Thursday, September 16, 2021 - 6:23pm

NEWYORK, Sept. 16, 2021 /PRNewswire/ --The National Advertising Division (NAD) of BBB National Programs determined that Almased USA, Inc.'s claim that its Almased Diet/Weight Loss Program is ".

Key Points: 
  • NEWYORK, Sept. 16, 2021 /PRNewswire/ --The National Advertising Division (NAD) of BBB National Programs determined that Almased USA, Inc.'s claim that its Almased Diet/Weight Loss Program is ".
  • so safe that even people with diabetes can use it" was supported.
  • NAD has determined that safety claims for dietary supplement products can be supported by reliable clinical studies that demonstrate that the product is safe.
  • About BBB National Programs:BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard.

Dr. Erika Krauss Joins Glenville Medical Concierge Care, Bringing Expertise in Internal Medicine, Integrative, and Metabolic Nutrition Medicine

Thursday, September 16, 2021 - 12:20pm

Now Glenville welcomes Erika S. Krauss, DO , a highly regarded internist with a unique background in integrative/functional and metabolic nutrition medicine.

Key Points: 
  • Now Glenville welcomes Erika S. Krauss, DO , a highly regarded internist with a unique background in integrative/functional and metabolic nutrition medicine.
  • I love practicing medicine this way, and my patients enjoy the difference from the moment they call the office.
  • "We are thrilled to work with Dr. Krauss and the Glenville Medical team to help bring her expertise in these in-demand specialties to the Greenwich community," says Terry Bauer, CEO, Specialdocs.
  • "Integrative or functional medicine is based on a holistic approach to preventing disease before it begins," explains Dr. Krauss.

Boxed Water™ and Conscious Brand Partners "Walk-the-Walk" for September's Coastal Clean Up Month with Organized Beach Cleans, "Plogging," and the Funding of a Microplastic Removal Machine

Thursday, September 16, 2021 - 12:01pm

Together, brand partners are pitching in funds to procure an additional microplastic extraction machine for the nonprofit, Ocean Blue Project (OBP).

Key Points: 
  • Together, brand partners are pitching in funds to procure an additional microplastic extraction machine for the nonprofit, Ocean Blue Project (OBP).
  • During September 15 through September 30, brand partners are also engaging consumer attention with a planet-conscious giveaway.
  • This year, Alaska announced a phased approach in swapping out plastic water bottles for Boxed Water.
  • Boxed Water was founded in the belief that sustainability matters with the purpose of changing the way packaged water is shipped, sold and enjoyed.

Luye Pharma enters into an agreement with ESTEVE to commercialize an Alzheimer's Disease Multi-Day Treatment Patch in Spain

Thursday, September 16, 2021 - 1:29am

BASEL, Switzerland, Sept. 16, 2021 /PRNewswire/ --Luye Pharma Switzerland AG ("Luye Switzerland"), a fully owned subsidiary of Luye Pharma Group (Luye Pharma), and Esteve Pharmaceuticals, S.A. (ESTEVE) announced today that they have entered into an agreement under which ESTEVE receives exclusive rights to commercialize the Rivastigmine Multi-Day Transdermal Patch in Spain.

Key Points: 
  • BASEL, Switzerland, Sept. 16, 2021 /PRNewswire/ --Luye Pharma Switzerland AG ("Luye Switzerland"), a fully owned subsidiary of Luye Pharma Group (Luye Pharma), and Esteve Pharmaceuticals, S.A. (ESTEVE) announced today that they have entered into an agreement under which ESTEVE receives exclusive rights to commercialize the Rivastigmine Multi-Day Transdermal Patch in Spain.
  • Xavier Valera, Managing Director Spain at ESTEVE commented: "This agreement allows ESTEVE to bring this innovative treatment to Spain and to complement our neurology-based portfolio in order to improve the quality oflife of our patients."
  • "The collaboration with ESTEVE represents an important milestone in our commitment to addressing unmet needs for senior patients in Europe.
  • Luye Pharma Group (Luye Pharma), a member of Luye Life Sciences Group, is an international pharmaceutical company dedicated to the R&D, manufacturing, and sale of innovative medications.

ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update

Wednesday, September 15, 2021 - 9:05pm

The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/z2wjhmw4 .

Key Points: 
  • The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/z2wjhmw4 .
  • An archived replay of the call will be available for 7 days by dialing + 1855859 2056, Conference ID: 6866536#.
  • ERYTECH is listed on the Nasdaq Global Select Market inthe United States(ticker: ERYP) and on theEuronext regulated market inParis(ISIN code: FR0011471135, ticker: ERYP).
  • ERYTECH is part of the CACHealthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

EvergreenHealth Weight Loss & Bariatric Care Achieves Comprehensive Center with Obesity Medicine Qualifications Accreditation

Wednesday, September 15, 2021 - 4:46pm

The Weight Loss & Bariatric Care practice at EvergreenHealth recently received accreditation as a Comprehensive Center with Obesity Medicine Qualifications by the American College of Surgeons and the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP).

Key Points: 
  • The Weight Loss & Bariatric Care practice at EvergreenHealth recently received accreditation as a Comprehensive Center with Obesity Medicine Qualifications by the American College of Surgeons and the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP).
  • The Weight Loss & Bariatric Care practices MBSAQIP accreditation acknowledges the health systems commitment to providing and supporting quality improvement and patient safety efforts for those seeking metabolic care and bariatric surgery.
  • This accreditation puts EvergreenHealth among the first 25 organizations in the nation to have achieved a dual center of excellence certification in bariatric surgery and obesity medicine.
  • All weight loss patients deserve highly personalized, expert clinical care delivered with compassion and respect, which are pillars of our practice, said Sonia Hans, MD, an obesity medicine expert at EvergreenHealth, who is board-certified in obesity medicine, endocrinology and internal medicine.

Hyperuricemia (Metabolic Disorder) Drugs In Development, 2021 Pipeline Landscape Report - ResearchAndMarkets.com

Wednesday, September 15, 2021 - 3:49pm

The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects.

Key Points: 
  • The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

Algorithm Sciences, a Laidlaw Venture Partners Portfolio Company, Announces Key Management Appointments

Wednesday, September 15, 2021 - 3:16pm

NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Laidlaw Venture Partners (LVP), the venture capital arm ofLaidlaw & Company (UK) Ltd., today announced key management appointments for its portfolio company, Algorithm Sciences, Inc.

Key Points: 
  • NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Laidlaw Venture Partners (LVP), the venture capital arm ofLaidlaw & Company (UK) Ltd., today announced key management appointments for its portfolio company, Algorithm Sciences, Inc.
  • James Ahern, Founding Partner, Laidlaw Venture Partners added, "Laidlaw Venture Partners is thrilled to have been able to attract the caliber of talent that Mike and David bring to Algorithm.
  • Matt is also Managing Partner of Laidlaw Venture Partners and Managing Director of Laidlaw and Company, Ltd. (UK).
  • Laidlaw Wealth Management and Laidlaw Private Equity, LLC are affiliates of Laidlaw & Company (UK) Ltd.
    Laidlaw Venture Partners is a DBA, of Laidlaw Private Equity.